Clinical Trial

A Study of IBI362 9 mg in Chinese Adults With Obesity

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 27, 2024 (before its estimated June 27, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-01; most recent amendment 2024-08-26.
Status change: Recruiting → Active, Not Recruiting 2024-08-26
Status change: Not Yet Recruiting → Recruiting 2024-04-30
Trial Details
NCT Number NCT06164873
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Obesity
Enrollment 462 participants
Start Date 2023-12-27
Primary Completion 2025-06-27 (estimated)
Study Completion 2025-09-19 (estimated)
Updated on ClinicalTrials.gov 2024-08-27